Ryuk Jun Kwon

Prof. Dr. Ryuk Jun Kwon

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
SSSOO MIN SON
SOO MIN SON
EPEun-Ju Park
Eun-Ju Park
Young Hye ChoYoung Hye Cho
Young Hye Cho
Sang Yeoup LeeSang Yeoup Lee
Sang Yeoup Lee
JCJung In Choi
Jung In Choi
CKChoongrak Kim
Choongrak Kim
Background: Many researchers have identified that adequate sleep duration is linked to the quality of life and metabolic diseases. Nowadays, it is hard to take enough sleep, so weekend catch-up sleep (CUS) may be an alternative option in modern society. To our knowledge, no previous studies reported the association between weekend CUS and metabolic syndrome, especially in the Korean population. Objective: We investigated the association between weekend CUS and the prevalence of metabolic syndrome in Korean adults (≥ 20 years old) with less than 6 hours of average weekday sleep. Patients and Methods: A total of 1,453 individuals were selected from the Korean National Health and Nutrition Examination Survey. Weekend CUS was divided into four categories: ≤ 0 hour, 0– 1 hour, 1– 2 hours, and ≥ 2 hours. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived by univariate and multivariate logistic regression analyses. Results: Participants with weekend CUS ≥ 1 hour had decreased risk of metabolic syndrome in univariate analysis (CUS 1– 2 hours: OR: 0.413, 95% CI: 0.301– 0.568; CUS ≥ 2 hours: OR: 0.382, 95% CI 0.296– 0.493). Weekend CUS 1– 2 hours reduced the risk of metabolic syndrome in multivariate logistic regression analysis (OR: 0.552, 95% CI: 0.369– 0.823). Based on the age group analysis, weekend CUS ≥ 1 hour reduced the metabolic syndrome among those aged 20– 39 and 40– 65 (20– 39: CUS 1– 2 hours OR: 0.248, 95% CI: 0.078– 0.783, CUS ≥ 2 hours OR: 0.374, 95% CI: 0.141– 0.991; 40– 65: CUS 1– 2 hours OR: 0.507, 95% CI 0.309– 0.832 CUS ≥ 2 hours OR: 0.638, 95% CI: 0.415– 0.981). Conclusion: Weekend CUS was associated with a low risk of metabolic syndrome among Korean adults with sleep restriction.

26 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YLYoung-Shin Lee
Young-Shin Lee
RKRyuk Jun Kwon
Ryuk Jun Kwon
HLHye Sun Lee
Hye Sun Lee
JCJae Heun Chung
Jae Heun Chung
YKYun Seong Kim
Yun Seong Kim
SYSeong Hoon Yoon
Seong Hoon Yoon
Lung cancer remains a major global health problem because of its high cancer-related mortality rate despite advances in therapeutic approaches. Non-small cell lung cancer (NSCLC), a major subtype of lung cancer, is more amenable to surgical intervention in its early stages. However, the prognosis for advanced NSCLC remains poor, owing to limited treatment options. This underscores the growing need for novel therapeutic strategies to complement existing treatments and improve patient outcomes. In recent years, pentacyclic triterpenoids, a group of natural compounds, have emerged as promising candidates for cancer therapy due to their anticancer properties. Pentacyclic triterpenoids, such as lupeol, betulinic acid, betulin, oleanolic acid, ursolic acid, glycyrrhetinic acid, glycyrrhizin, and asiatic acid, have demonstrated the ability to inhibit cell proliferation and angiogenesis, induce apoptosis, suppress metastasis, and modulate inflammatory and immune pathways in NSCLC cell line models. These compounds exert their effects by modulating important signaling pathways such as NF-κB, PI3K/Akt, and MAPK. Furthermore, advances in drug delivery technologies such as nanocarriers and targeted delivery systems have improved the bioavailability and therapeutic efficacy of triterpenoids. However, despite promising preclinical data, rigorous clinical trials are needed to verify their safety and efficacy. This review explores the role of triterpenoids in NSCLC and therapeutic potential in preclinical models, focusing on their molecular mechanisms of action.

29 September 2025 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YLYohwan Lim
Yohwan Lim
EKEunji Kim
Eunji Kim
EHEunjung Hwang
Eunjung Hwang
KKKoanhoi Kim
Koanhoi Kim
YSYonghae Son
Yonghae Son
RKRyuk Jun Kwon
Ryuk Jun Kwon
Section Background Lipid-lowering therapies, particularly statins, have been associated with a reduced risk of cancer. However, the potential additional protective effects of ezetimibe remain unclear in real-world settings. This study investigated whether statin/ezetimibe combination therapy provided further cancer risk reduction beyond statin monotherapy. AbstractSection Methods A nationwide retrospective cohort study was conducted using the Korean National Health Insurance Service database. Patients with dyslipidemia (total cholesterol ≥ 240 mg/dL) diagnosed between 2004 and 2009 were included and categorized into statin users, statin/ezetimibe users, and nonusers. Cancer incidence over 5- and 10-year follow-up periods was assessed using Cox proportional hazards models adjusted for demographic, clinical, and lifestyle factors. Inverse probability of treatment weighting (IPTW) was applied to account for potential confounders, and sensitivity analyses were performed to assess the stability of the findings. AbstractSection Results Among 68,353 patients, 9,267 were statin users, 383 were statin/ezetimibe users, and 58,703 were nonusers. Statin users exhibited a reduced cancer risk at 5 years (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI] 0.80–0.89) and 10 years (aHR, 0.91; 95% CI 0.87–0.94). Statin/ezetimibe users demonstrated a greater reduction in cancer risk (5 years: aHR, 0.30; 95% CI 0.28–0.32; 10 years: aHR, 0.70; 95% CI 0.67–0.73). Trend analysis confirmed an incremental trend in cancer risk reduction with increasing lipid-lowering therapy intensity (P for trend < 0.001). AbstractSection Conclusion This real-world study suggests that ezetimibe, when combined with statins, is associated with additional cancer risk reduction beyond statin monotherapy, as observed across both overall and direct comparative analyses. Further research is warranted to confirm the independent effects of ezetimibe and its potential role in cancer prevention.

20 August 2024 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
DLDahae Lim
Dahae Lim
JCJung In Choi
Jung In Choi
RKRyuk Jun Kwon
Ryuk Jun Kwon
Sang Yeoup LeeSang Yeoup Lee
Sang Yeoup Lee
Young Hye ChoYoung Hye Cho
Young Hye Cho
YRYoung Jin Ra
Young Jin Ra
Insulin resistance contributes to the development of cardiovascular disease and type 2 diabetes mellitus. Smoking leads to an increase in triglyceride levels, which, in turn, increases insulin resistance. Although the number of e-cigarette users has increased in recent years, few studies have investigated the association between ecigarette use and insulin resistance. Therefore, this study aimed to determine the association between e-cigarette use and insulin resistance using the triglyceride-glucose (TyG) index in Korean adults. This study included 4,404 healthy adults aged ≥20 years who participated in the Korea National Health and Nutrition Examination Survey between 2019 and 2020. Participants were categorized as never-smokers or ecigarette users, and the TyG index was categorized into low- and high-TyG index groups according to the median value (9.22). A logistic regression analysis was performed to determine the association between e-cigarette smoking and insulin resistance. E-cigarette users had a higher TyG index than never smokers (e-cigarette: mean=3.95; never: mean=9.18; P<0.001). The e-cigarette users had a higher risk of being in the high TyG index group than never-smokers (odds ratio [OR], 1.38; 95% confidence interval [CI], 1.03-1.84). In the subgroup analysis stratified by sex, age, and body mass index, a higher OR for a high TyG index was observed in men (OR, 1.46; 95% CI, 1.03-2.08) and individuals aged 60 years or older (OR, 3.74; 95% CI, 1.14-12.30). Our findings suggest that e-cigarette use is significantly associated with insulin resistance.

1 May 2024 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
SSSoo Min Son
Soo Min Son
HLHye Sun Lee
Hye Sun Lee
JKJeongsu Kim
Jeongsu Kim
RKRyuk Jun Kwon
Ryuk Jun Kwon
Background: Glioblastoma (GBM) is the most common malignant brain tumor and has poor survival. An elevated cholesterol level is involved occurrence and progression of brain tumors. Microsomal triglyceride transfer protein (MTTP) is a target for lowering lipids, and its inhibition helps to improve hyperlipidemia. However, whether the altered expression of MTTP affects the development and prognosis of brain tumors is currently unidentified. The purpose of this study is to determine MTTP as a prognostic marker for brain tumors. Methods: Data for patients with brain cancers and control brain tissue were acquired from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The datasets were analyzed using Mann-Whitney U-test or t-test to compare the expression of MTTP in normal and brain tumor tissues. To examine whether MTTP affected the prognosis of patients with brain tumors, log-rank test and multivariable Cox proportional hazard regression were conducted. Results: The expression of MTTP was significantly upregulated in brain tumors and was correlated with age, tumor stage, and isocitrate dehydrogenase (IDH) mutation. Importantly, increased MTTP expression in brain tumors is associated with poor patient survival. Conclusions: High MTTP expression is associated with brain tumor development, tumor stage, and prognosis. Therefore, MTTP is an independent prognostic indicator for brain tumors, which can serve as one of the possible targets for adjuvant treatment of GBM.

Verified
Journal Article
Open access
PDF file
KKKoanhoi Kim
Koanhoi Kim
HCHyok-rae Cho
Hyok-rae Cho
BKBo-Young Kim
Bo-Young Kim
JKJaesung Kim
Jaesung Kim
DPDongha Park
Dongha Park
YSYonghae Son
Yonghae Son
Microglia, essential immune cells in the brain, play crucial roles in neuroinflammation by performing various functions such as neurogenesis, synaptic pruning, and pathogen defense. These cells are activated by inflammatory factors like β-amyloid (Aβ) and oxysterols, leading to morphological and functional changes, including the secretion of inflammatory cytokines and the upregulation of MHC class II molecules. This study focused on identifying specific markers for microglial activation, with a particular emphasis on the roles of oxysterols in this process. We used the HMC3 human microglial cell line to investigate the induction of heat shock protein 60 (HSP60), a chaperonin protein by oxysterols, specifically in the presence of 25-hydroxycholesterol (25OHChol) and 27-hydroxycholesterol (27OHChol). Our findings obtained by the proteomics approach revealed that these oxysterols significantly increased HSP60 expression on microglial cells. This induction was further confirmed using Western blot analysis and immunofluorescence microscopy. Additionally, Aβ1–42 also promoted HSP60 expression, indicating its role as a microglial activator. HSP60 involved in protein folding and immune modulation was identified as a potential marker for microglial activation. This study underscores the importance of HSP60 in the inflammatory response of microglia, suggesting its utility as a target for new therapeutic approaches in neuroinflammatory diseases such as Alzheimer’s disease (AD).